Business Description
Inhibitor Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US45720M1053
Total Employee Number:
8Description
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.26 | |||||
Equity-to-Asset | -1.38 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.88 | |||||
9-Day RSI | 50.31 | |||||
14-Day RSI | 49.51 | |||||
3-1 Month Momentum % | -11.11 | |||||
6-1 Month Momentum % | 2.83 | |||||
12-1 Month Momentum % | 46.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.6 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 3.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 0.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -108.22 | |||||
ROIC % | -3511.2 | |||||
3-Year ROIIC % | 858.19 | |||||
ROC (Joel Greenblatt) % | -4204.88 | |||||
ROCE % | -122.96 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -3.65 | |||||
EV-to-EBITDA | -3.65 | |||||
EV-to-FCF | -4.15 | |||||
Earnings Yield (Greenblatt) % | -27.4 | |||||
FCF Yield % | -21.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INTI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibitor Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.01 | ||
| Beta | -0.6333 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.35 | ||
| Volatility % | 88.71 | ||
| 14-Day RSI | 49.51 | ||
| 14-Day ATR ($) | 0.002107 | ||
| 20-Day SMA ($) | 0.078853 | ||
| 12-1 Month Momentum % | 46.25 | ||
| 52-Week Range ($) | 0.0351 - 0.12375 | ||
| Shares Outstanding (Mil) | 172.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibitor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibitor Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibitor Therapeutics Inc Frequently Asked Questions
What is Inhibitor Therapeutics Inc(INTI)'s stock price today?
The current price of INTI is $0.08. The 52 week high of INTI is $0.12 and 52 week low is $0.04.
When is next earnings date of Inhibitor Therapeutics Inc(INTI)?
The next earnings date of Inhibitor Therapeutics Inc(INTI) is .
Does Inhibitor Therapeutics Inc(INTI) pay dividends? If so, how much?
Inhibitor Therapeutics Inc(INTI) does not pay dividend.
Guru Commentaries on OTCPK:INTI
No articles.
Press Release
Articles on Inhibitor Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers